Examine Emerging Opportunities in Cancer Nanomedicine With This New Report
Nanomedicine has applications across the field of anticancer treatments - but what are the likely outcomes for key areas?
Using "Optimistic, Realistic and Pessimistic" scenarios, the report assesses what success key nanotechnologies will have on treating oncology in the following areas:
Molecular imaging and early detection
Nanotechnology possesses the ability to have an early, paradigm-changing impact on how clinicians will detect cancer in its earliest stages. Devices constructed of nanoscale components, such as nanocantilevers, nanowires and nanochannels, offer the potential for detecting even the rarest molecular signals associated with malignancy.
In vivo imaging
One of the most urgent requirements in clinical oncology is for imaging agents that can identify tumours that are far smaller than those detectable with today's technology, at a scale of 1x105 cells rather than 1x109 cells. Achieving this level of sensitivity requires better targeting of imaging agents and the generation of a bigger imaging signal, both of which nanoscale devices are capable of accomplishing.
Reporters of efficacy
Nanotechnology offers the potential for developing highly-sensitive imaging agents and ex vivo diagnostics that can determine whether a therapeutic agent is reaching its intended target and whether that agent is killing malignant or support cells, such as growing blood vessels.
Because of their multi-functional capabilities, nanoscale devices can contain both targeting agents and therapeutic payloads at levels that can produce high local concentrations of a given anticancer drug. This is beneficial in areas of the body that are difficult to access because of a variety of biological barriers, including those developed by tumours.
Prevention and control
Many of the advances that nanotechnology will enable in each of the four preceding challenge areas will also find widespread applicability in efforts to prevent and control cancer. Advances driven by proteomics and bioinformatics are enabling researchers to identify markers of cancer susceptibility and precancerous lesions. Nanotechnology will then be used to develop devices that are capable of signalling when those markers appear in the body and deliver agents that would reverse premalignant changes or kill those cells that have the potential for becoming malignant.
Nanotechnology offers a wide range of tools, from chip-based nanolaboratories that are capable of monitoring and manipulating individual cells to nanoscale probes that can track the movements of cells, and even individual molecules, as they move about in their environment. Using such tools will enable cancer biologists to study, monitor and alter the multiple systems that go awry in the cancer process, and identify key biochemical and genetic points at which future molecular therapies might best be directed.
Current products evaluated...
- Abraxane - Abraxis BioScience/AstraZeneca - DaunoXome - Gilead Sciences/Diatos - CellSearch Circulating Tumor Cell Kit - Immunicon - Bio-barcode and Verigen platform - Nanosphere - Caelyx/Doxil - Ortho Biotech - Myocet - Zeneus Pharma Novel research by academic institutions evaluated... Over 30 leading research bodies are conducting cancer nanomedicine research worldwide. Companies Mentioned Include: - Ablynx - Acusphere - Advanced Magnetics/Cytogen - ADVENTRX Pharmaceuticals - Alnis Biosciences - Aphios - Celsion - Dendritic Technologies/Starpharma - Flamel Technologies - INEX Pharmaceuticals - Insert Therapeutics (Arrowhead Research) - Intradigm - Introgen Therapeutics - Kereos - Keystone Nano - LiPlasome Pharma - MagForce Nanotechnologies - Mersana Therapeutics - Nanobiotix - NanoCarrier - Nanolution (Biophan Technologies) - NanoMed Pharmaceuticals - Nanospectra Biosciences - Pro-Pharmaceuticals
For more information visit http://www.researchandmarkets.com/reports/c41593